Intrinsic Tumour Factors Affecting Recurrence in Non Muscle Invasive Bladder Cancer: a Hospital Based Study from India

  • Mehta, Nisarg (Department of Urology, Lourdes Hospital) ;
  • Rathore, Ranjeet Singh (Department of Urology, Lourdes Hospital) ;
  • Pillai, Biju S (Department of Urology, Lourdes Hospital) ;
  • Sam, Mohan P (Department of Urology, Lourdes Hospital) ;
  • Moorthy, Krishna (Consultant, Lourdes Hospital)
  • Published : 2015.04.14


Background: Depending on various pathological factors, non muscle invasive bladder cancer (NMIBC) shows varying degrees of recurrence. The aim of this study was to determine the incidence of recurrence of NMIBS in our centre, study the influence of intrinsic tumour characteristics like grade, stage, size and number, and compare our results with data in the published literature. Materials and Methods: A hospital based retrospective study was conducted on patients who underwent treatment for NMIBC from 2011 to 2014. The factors studied were number, size, grade, stage and site for correlation with recurrence. Statistical analysis was performed using Medcalc version 12, using Pearson's Chi square test to ascertain associations between variables. Results: A total of 73 patients with NMIBC were studied of which 48 (65.8%) had low grade and 25 (34.2%) had high grade tumours. Some 38 patients (52.1%) had Ta tumours, 34 (46.6%) had T1 and one had CIS. Mean follow up was 34.3 months. Recurrence rates were found to be 33.3% in low grade and 52.0% in high grade tumours. The overall recurrence rate in our centre was 39.7%. Significant correlations were seen between stage and recurrence, with a rate of 15% for Ta and 63.3% for T1 tumours. Fourteen out of 21 bladder cancers (66.6%) with multiple tumours demonstrated recurrence (p=0.006). Grade, size and site had no influence. Conclusions: In our study, recurrence of NMIBC was found to be directly proportional to stage and number of primary tumours, but not grade, size and site. The incidence of recurrence of NMIBC both stage wise and grade wise in our centre was also low compared to the data in the published literature.


Transitional cell carcinoma;NMIBC;recurrence;tumour factors


  1. Ali-El-Dein B, Sarhan O, Hinev A, et al (2003). Superficial bladder tumours: Analysis of prognostic factors and construction of a predictive index. BJU Int, 92, 393-9.
  2. Badar F, Sattar A, Meerza F, Irfan N, Siddiqui N (2009). Carcinoma of the urinary bladder in a tertiary care setting in a developing country. Asian Pac J Cancer Prev, 10, 449-2
  3. Brausi M, Collette L, Kurth K, et al (2002). EORTC Genito-Urinary Tract Cancer Collaborative Group: Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta\T1 transitional Cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 41, 523-1.
  4. Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-3.
  5. Hall CM, Chang SS, Dalbagni G, et al (2007). Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 Update from the American Urological Association Education and Research, Inc J Urol, 178, 2314-0
  6. Heney NM, Nocks BN, Daly JJ, et al (1982). Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol, 52, 152-7
  7. Herr HW (2000). Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol, 163, 60-1
  8. Jemal A, Bray F, Center MM, et al. Global cancer statistics (2011). CA Cancer J Clin, 61, 69-0.
  9. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer (2000). J Urol, 163, 73-8.
  10. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer (2004). Minerva Urol Nephrol, 56, 65-2.
  11. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C (2006). Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol, 3, 327-0.
  12. Salehi A, Khezri A, Malekmakan L, Aminsharifi A (2011). Epidemiologic status of bladder cancer in Shiraz, Southern Iran. Asian Pac J Cancer Prev, 12, 1323-7.
  13. Shakhssalim N, Hosseini SY, Basiri A, et al (2010). Prominent bladder cancer risk factors in Iran. Asian Pacific J Cancer Prev, 11, 601-6.
  14. Supit W, Mochtar CA, Sugiono M, Umbas R (2011). Survival of patients with transitional cell carcinoma of the urinary bladder in Indonesia: A single institution review. Asian Pac J Cancer Prev, 12, 549-3
  15. Sylvester RJ, Van der Meijden AP, Oosterlinck W, et al (2006). Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 3, 466-5.
  16. Wu X, Ros MM, Gu J, Kiemeney L (2008). Epidemiology and genetic susceptibility to bladder cancer. BJU Int, 102, 1207-5.
  17. Yaris F, Dikici MF, Sabuncu HH, Yaris E (2006). A case-control study on the etiology of urinary bladder cancer in Istanbul, Turkey. Asian Pac J Cancer Prev, 7, 591-4.
  18. Yavari P, Sadrolhefazi B, Mohagheghi MA, Mehrazin R (2009). A descriptive retrospective study of bladder cancer at a hospital in Iran (1973-2003). Asian Pac J Cancer Prev, 10, 681-4.
  19. Zeegers MP, Tan FE, Dorant E, van der Brandt PA (2000). The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer, 89, 630-9.<630::AID-CNCR19>3.0.CO;2-Q

Cited by

  1. Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder vol.17, pp.4, 2016,